Fundraising Fox

Recursion Pharmaceuticals

NASDAQ: RXRX

Salt Lake City, US · Founded 2013 · Delaware corporation · 7 known investors

Biotech

Founders & leadership

Recursion Pharmaceuticals was founded in 2013 by Blake C. Borgeson and Christopher C. Gibson.

BC
Blake C. BorgesonCo-founder
CC
Christopher C. GibsonCo-founder
DY
Dean Y. YiExecutive
CC
Christopher C GibsonNamed on SEC filing

Investors · 7

Amplify PartnersMenlo Park · $500K – $5M
Manta Ray VenturesLondon
Obvious VenturesSan Francisco · $250K – $6M
CRV (Charles River Ventures)reportedBay Area · $250K – $5M
DCVC (Data Collective)reportedPalo Alto · $5M – $25Mvia Zachary Bogue · board
Lux CapitalreportedNew York · $100K – $100M
Menlo VenturesreportedSan Francisco · $1M – $20M

Reported raises · per SEC filings

Form D private placements

$478.4M disclosed across 9 rounds · 2014–2020

▶$245.9MraisedNov 2020 · 49 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • ROBERT HERSHBERGDirector
  • R. MARTIN CHAVEZDirector
  • MICHAEL SECORAExecutive Officer, Promoter
  • DEAN LIDirector
  • ZACHARY BOGUEDirector
  • ZAVAIN DARDirector
  • BLAKE BORGESONDirector
  • CHRISTOPHER C. GIBSONExecutive Officer, Director, Promoter
  • TERRY-ANN BURRELLDirector
Offering amount
$245.9M
Amount sold
$245.9M
First sale
Sep 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$122.1MraisedAug 2019 · 33 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • ZACHARY BOGUEDirector
  • ZAVAIN DARDirector
  • CHRISTOPHER C. GIBSONExecutive Officer, Director, Promoter
  • BLAKE BORGESONDirector
  • DEAN LIDirector
Offering amount
$122.1M
Amount sold
$122.1M
Sales commissions
$2.1M
Placement agents
ALLEN & COMPANY
First sale
Feb 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$55.8MraisedOct 2017 · 26 investors · Pharmaceuticals
Rule 506(b)
Drug discovery startup Recursion Pharmaceuticals raises $60m Series Btechcrunch.com · Oct 2017
Officers, directors & promoters on the filing
  • H. PERRY FELLDirector
  • ZACHARY BOGUEDirector
  • ZAVAIN DARDirector
  • CHRISTOPHER C. GIBSONExecutive Officer, Director, Promoter
  • BLAKE BORGESONExecutive Officer, Director, Promoter
  • JOHN PEREIRAExecutive Officer
Offering amount
$60M
Amount sold
$55.8M
First sale
Sep 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15MraisedDec 2016 · 18 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • DEAN Y. LIExecutive Officer, Promoter
  • BLAKE C. BORGESONExecutive Officer, Director, Promoter
  • REID HUTCHINSDirector
  • CHRISTOPHER C. GIBSONExecutive Officer, Director, Promoter
  • H. PERRY FELLDirector
  • ZAVAIN DARDirector
Offering amount
$15M
Amount sold
$15M
First sale
Sep 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$32MraisedSep 2016 · 32 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • REID HUTCHINSDirector
  • CHRISTOPHER C. GIBSONExecutive Officer, Director, Promoter
  • ZAVAIN DARDirector
  • BLAKE C. BORGESONExecutive Officer, Director, Promoter
  • H. PERRY FELLDirector
  • DEAN Y. LIExecutive Officer, Director, Promoter
Offering amount
$32M
Amount sold
$32M
First sale
Sep 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.1MraisedSep 2016 · 31 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • ZAVAIN DARDirector
  • CHRISTOPHER C. GIBSONExecutive Officer, Director, Promoter
  • DEAN LIExecutive Officer, Director, Promoter
  • BLAKE BORGESONExecutive Officer, Director, Promoter
  • H. PERRY FELLDirector
  • REID HUTCHINSDirector
Offering amount
$4.1M
Amount sold
$4.1M
First sale
Sep 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.6MraisedDec 2015 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher GibsonExecutive Officer, Director
  • Perry FellDirector
  • Blake BorgesonExecutive Officer, Director
  • Dean LiExecutive Officer, Director
Offering amount
$2.7M
Amount sold
$2.6M
Minimum investment
$5K
Proceeds to insiders
$20K
First sale
Nov 2015
Incorporated
Limited Liability Company, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$830KraisedFeb 2015 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Blake C. BorgesonExecutive Officer, Director
  • Dean Y. YiExecutive Officer, Director
  • Christopher C. GibsonExecutive Officer, Director
Offering amount
$1M
Amount sold
$830K
Minimum investment
$1K
Proceeds to insiders
$40K
First sale
Feb 2015
Incorporated
Limited Liability Company, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Recursion Pharmaceuticals, Inc. $RXRX Stake Increased by California State Teachers Retirement System - Defense Worlddefenseworld.net · Aug 2026Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: Potential Upside Of Over 120% Sparks Investor Interestdirectorstalkinterviews.com · Aug 2026Recursion Pharmaceuticals (RXRX) Reported Q2 Revenue Pressure, Is The Valuation Gap Too Wide? - Simply Wall St Newssimplywall.st · Aug 2026Recursion Pharmaceuticals (RXRX) Stock Still Looks Expensive Following August 5 Results Updatefinance.yahoo.com · Aug 2026Recursion Pharmaceuticals (RXRX): Investor Outlook On A Biotech Pioneer With 127.99% Potential Upsidedirectorstalkinterviews.com · Aug 2026Drug discovery startup Recursion Pharmaceuticals raises $60m Series Btechcrunch.com · Oct 2017

Frequently asked questions

Who founded Recursion Pharmaceuticals?
Recursion Pharmaceuticals was founded by Blake C. Borgeson, Christopher C. Gibson in 2013.
Who are Recursion Pharmaceuticals's investors?
Recursion Pharmaceuticals's investors include Amplify Partners, Manta Ray Ventures, Obvious Ventures, CRV (Charles River Ventures), DCVC (Data Collective), Lux Capital, Menlo Ventures.
How much funding has Recursion Pharmaceuticals raised?
Recursion Pharmaceuticals has disclosed $478.4M raised across 9 rounds.
Where is Recursion Pharmaceuticals headquartered?
Recursion Pharmaceuticals is headquartered in Salt Lake City, US.